Also, a previous meta-analysis by Monami et al. found that GLP-1 RAs, including lixisenatide, liraglutide, dulaglutide, semaglutide, exenatide, and albiglutide, reduced cardiovascular mortality and the incidence of MI in T2DM patients compared with placebo or other non-GLP-1 RA treatments. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.